Recommended
product-img
  • Products
  • Discover MP Targets
  • Discover Research Areas
  • mProX™ Human RET Stable Cell Line

    [CAT#: S01YF-1023-PY85]
    Product Category:
    Membrane Protein Stable Cell Lines
    Subcategory:
    Kinase Cell Lines

    Datasheet MSDS Request COA

    Certificate of Analysis Lookup
    To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
    Lot Number

    Made to Order Inquiry

    Inquiry
    Host Cell Type:
    Membrane Protein Engineering:
    Fluorescent Marker:
    Resistance:
    Deliverable:

    Product Information

    Target Family
    Kinases/Enzyme
    Target Protein Species
    Human
    Host Cell Type
    HEK293;CHO-K1;LNCap
    Target Classification
    Kinase Cell Lines
    Target Research Area
    CNS Research
    Related Diseases
    Hirschsprung Disease 1; Multiple Endocrine Neoplasia, Type Iia
    Gene ID
    Human:5979
    UniProt ID
    Human:P07949

    Product Properties

    Biosafety Level
    Level 1
    Activity
    Yes
    Quantity
    10⁶ cells per vial
    Applications
    RET (rearranged during transfection) is a gene that encodes a receptor tyrosine kinase involved in various cellular processes. It has been found to be implicated in several diseases, including histiocytic neoplasms, differentiated thyroid cancer, and papillary thyroid carcinoma. In histiocytic neoplasms, activating alterations in RET, along with other genes such as ALK and CSF1R, have shown anecdotal evidence of successful targeted treatment. In pediatric thyroid tumors and differentiated thyroid cancer, fusions involving the RET gene, as well as other genetic alterations like ALK and BRAF, have been identified. In papillary thyroid carcinoma, a long non-coding RNA called PFAR has been found to facilitate tumor proliferation and migration by mediating the miR-15a/RET axis. Additionally, the RET inhibitor selpercatinib has shown promise in treating RET-mutated medullary thyroid cancer and RET fusion-positive non-small cell lung cancer. These findings highlight the importance of tumor sequencing and personalized treatment approaches in targeting RET alterations in various diseases.

    Protocols

    Please visit our protocols page.

    Customer Reviews

    There are currently no Customer reviews or questions for mProX™ Human RET Stable Cell Line (S01YF-1023-PY85). Click the button above to contact us or submit your feedback about this product.

    FAQ

    chat Skyler Brown (Verified Customer)

    What is the role of RET in cancer and how are RET inhibitors used in therapy? Apr 01 2022

    chat Patrick Liam (Creative Biolabs Scientific Support)

    RET is a receptor tyrosine kinase involved in various cancers, and selective RET inhibitors like pralsetinib and selpercatinib have shown efficacy in treating RET fusion-positive tumors, including lung and thyroid cancers. Apr 01 2022

    chat Skyler Johnson (Verified Customer)

    How does RET gene alteration affect cancer prognosis? Mar 29 2021

    chat Patrick Liam (Creative Biolabs Scientific Support)

    Alterations in the RET gene can significantly impact the progression and prognosis of certain cancers, making it a critical target in precision oncology. Mar 29 2021
    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR CLINICAL PROCEDURES" For licensing inquiries, please contact
    Send Inquiry Send Inquiry
    Inquiry Basket
    compare

    Go to compare